Using inhaled nitroglycerin to improve breathing in late-stage COPD patients
"The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"
This study is testing if inhaled nitroglycerin can help people with late-stage COPD breathe better and improve their lung function.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Haram, Giza Governorate) |
| Trial ID | NCT06785337 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of nebulized nitroglycerin on respiratory function in patients with late-stage Chronic Obstructive Pulmonary Disease (COPD). The approach focuses on the vasodilation of pulmonary arteries and arterioles, which can alleviate ventilation/perfusion mismatching that exacerbates COPD symptoms. Additionally, the study aims to enhance antibiotic delivery to the alveoli, potentially improving infection control in these patients. It is designed as an interventional study, encompassing both Phase 2 and Phase 3 evaluations.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with COPD exacerbation and evidence of pulmonary hypertension.
Not a fit: Patients with profound left ventricular failure, pregnant women, or those with hypersensitivity to nitroglycerin may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve respiratory function and quality of life for patients with severe COPD.
How similar studies have performed: While the use of inhaled nitroglycerin is a novel approach in this context, similar studies have shown promise in improving respiratory outcomes in other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient's ≥ 18 years old COPD exacerbation with respiratory failure and Echo evidenced presence of pulmonary hypertension (defined as mean pulmonary artery pressure \> 20 mmHg) Exclusion Criteria: * Profound left ventricular failure, as the decrease in pulmonary vascular resistance results in an increase in left ventricular preload. This may worsen cardiogenic pulmonary edema. * Pregnant female patients * Patient with hypersensitivity to nitroglycerin
Where this trial is running
Haram, Giza Governorate
- Haram Hospital — Haram, Giza Governorate, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.